Investigational Products
AT177 and Azora Therapeutics’ other product candidates are investigational and have not been approved
by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not
been established, and no conclusion regarding safety or efficacy can or should be drawn from the information
presented on this website. Clinical and preclinical findings described here, including findings relating to
indigo naturalis, are drawn from published third-party research and from company data on file; results
observed with any other agent are not predictive of results that may be observed with AT177. Nothing on this
site is medical advice, an offer to sell or a solicitation to buy any security, or a promotion of any
unapproved product or unapproved use of a product.
Trademarks
Azora™, Azora Therapeutics and the Azora logo are trademarks of Azora Therapeutics, Inc. All other
product names, logos, brands and trademarks appearing on this site are the property of their respective
owners. Their use does not imply any affiliation with, endorsement or sponsorship by, or partnership with
those owners, and Azora Therapeutics asserts no ownership of or right in those marks. Where third-party
products are referenced, they are referenced solely to describe the prior professional experience of members
of Azora’s team and advisors.
Forward-Looking Statements
This website contains "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements regarding the development of AT177, planned IND filing and clinical
trials, anticipated timing of data, market opportunity, and intellectual property. These statements are based
on current expectations and assumptions and are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially. Product candidates are investigational, have not been
approved by the FDA or any regulatory authority, and their safety and efficacy have not been established.
Market, competitive, and clinical figures presented are drawn from company materials and third-party sources
and are subject to review. Azora undertakes no obligation to update any forward-looking statement except as
required by law. Please refer to the company's filings with the U.S. Securities and Exchange Commission for
additional information.
NASDAQ: AZR · © 2026 Azora Therapeutics, Inc. All rights reserved.
· Privacy Policy · Terms of Use · Accessibility
Statement